Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
901 to 920 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Applying CRISPR-Cas9 screens to dissect hematological malignancies. | Blood Adv | 2023 | 36355853 | PubTator, text mining | PubMed |
| Chemical degradation of BTK/TEC as a novel approach to inhibit platelet function. | Blood Adv | 2023 | 36342848 | PubTator, text mining | PubMed |
| Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders. | Nat Chem Biol | 2023 | 36329119 | PubTator, text mining | PubMed |
| Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. | Cancer Commun (Lond) | 2023 | 36316602 | PubTator, text mining | PubMed |
| An MDM2 degrader for treatment of acute leukemias. | Leukemia | 2023 | 36309559 | PubTator, text mining | PubMed |
| Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug. | J Enzyme Inhib Med Chem | 2023 | 36305287 | PubTator, text mining | PubMed |
| Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models. | Blood Adv | 2023 | 36269842 | PubTator, text mining | PubMed |
| HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation. | Cell Mol Gastroenterol Hepatol | 2023 | 36244648 | PubTator, text mining | PubMed |
| Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma. | Blood | 2023 | 36223594 | PubTator, text mining | PubMed |
| The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer. | Clin Transl Oncol | 2023 | 36203075 | PubTator, text mining | PubMed |
| ΔNp63α in cancer: importance and therapeutic opportunities. | Trends Cell Biol | 2023 | 36115734 | PubTator, text mining | PubMed |
| Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. | J Clin Oncol | 2023 | 35960908 | PubTator, text mining | PubMed |
| Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs). | Biochemistry | 2023 | 35948047 | PubTator, text mining | PubMed |
| Targeting cereblon in hematologic malignancies. | Blood Rev | 2023 | 35933246 | PubTator, text mining | PubMed |
| BRD4 and MYC: power couple in transcription and disease. | FEBS J | 2023 | 35866356 | PubTator, text mining | PubMed |
| Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic. | Biochemistry | 2023 | 35856839 | PubTator, text mining | PubMed |
| The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells. | Haematologica | 2023 | 35770527 | PubTator, text mining | PubMed |
| SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide. | Cancer Gene Ther | 2023 | 35338347 | PubTator, text mining | PubMed |
| Ligandability of E3 Ligases for Targeted Protein Degradation Applications. | Biochemistry | 2023 | 34473924 | PubTator, text mining | PubMed |
| Towards design of drugs and delivery systems with the Martini coarse-grained model. | QRB Discov | 2022 | 37529288 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=46